Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27302154 | 0.83 | ELANE (0.30) | ELANE | |
| SCHEMBL13184246 | 0.83 | ALDH1A1 (0.35) | ELANE | |
| SCHEMBL27050824 | 0.83 | HTT (0.43) | ELANE | |
| SCHEMBL24819184 | 0.83 | NOS3 (0.33) | ELANE | |
| SCHEMBL288578 | 0.83 | ELANE (0.30) | ELANE | |
| SCHEMBL24819186 | 0.83 | NOS3 (0.33) | ELANE | |
| SCHEMBL27050828 | 0.83 | SLC6A2 (0.39) | — | |
| SCHEMBL288315 | 0.83 | F2RL1 (0.32) | ELANE | |
| SCHEMBL13184290 | 0.83 | ALDH1A1 (0.35) | ELANE | |
| SCHEMBL24437008 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370740-B2 | Method for producing ester group-containing compound | DIC CORPORATION (JP) | 2022-06-28 | — | — | US | disclosed |
| EP-3247701-B1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11046889-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2021-06-29 | — | — | US | disclosed |
| US-10649124-B2 | Composition including compound having mesogenic group, polymer and optically anisotropic body obtained by polymerizing polymerizable composition, and phase difference film | DIC CORPORATION (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190025490-A1 | COMPOSITION INCLUDING COMPOUND HAVING MESOGENIC GROUP, POLYMER AND OPTICALLY ANISOTROPIC BODY OBTAINED BY POLYMERIZING POLYMERIZABLE COMPOSITION, AND PHASE DIFFERENCE FILM | DIC CORPORATION (JP) | 2019-01-24 | — | — | US | disclosed |
| WO-2017079867-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-05-18 | — | — | WO | disclosed |
| WO-2016118638-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-8980920-B2 | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8895768-B2 | Cyclopara (hetero) arylene compound and method for producing same | KYOTO UNIVERSITY (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
| WO-2011009084-A2 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010140685-A1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | 日産化学工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ELANE 2398/4885CCR1 4808/4885CCR5 4183/4885 |
| US-11370740-B2 | Method for producing ester group-containing compound | COASY, TAF5, TAF9 | ELANE 374/4885CCR1 2159/4885CCR5 1731/4885 |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | ELANE 17/4885CCR1 590/4885CCR5 573/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ELANE 1545/4885CCR1 4798/4885CCR5 4130/4885 |
| US-11046889-B2 | Polymerizable compound and optically anisotropic body | OCIAD1, RCC1, OCIAD2 | ELANE 3083/4885CCR1 595/4885CCR5 4605/4885 |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | ELANE 2013/4885CCR1 1657/4885CCR5 2257/4885 |
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | ELANE 572/4885CCR1 3762/4885CCR5 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.